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Interventional Cardiology
Registry Data Suggest No Difference
Between Eptifibatide and Abciximab for Primary PCI
Strong clinical trial results exist suggesting that abciximab improves outcomes inprimary percutaneous coronary intervention (PCI) for acute ST-segment elevation
myocardial infarction. Eptifibatide has less evidence for this indication. Gurm and
colleagues studied the use of these 2 agents for patients undergoing primary PCI in a
registry of over 3,000 patients. Eptifibatide was used nearly 4 times more often than
abciximab; there were no differences in the incidence of in-hospital death, recurrent
myocardial infarction, stroke/transient ischemic attack, or the need for blood transfu-
sion. These results suggest that eptifibatide, used as the adjunct antiplatelet agent in the
majority of patients undergoing primary PCI, appears to be as safe and efficacious as
abciximab. See page 529. See figure.
Myocardial Infarction
Newer Methods to Measure No-Reflow
Assessment of the no-reflow phenomenon after successful primary percutaneouscoronary intervention (PCI) traditionally relies on subjective measures such as
Thrombolysis InMyocardial Infarction flow and myocardial blush grade. Fearon and
colleagues used a pressure/themistor wire placed distally in the culprit vessel after PCI
to measure pressure and flow, which was then used to calculate resistance in the
microcirculation. The calculated resistance correlated more strongly with echocardio-
graphic wall motion score than other measurements of no-reflow. The AMICI (Acute
Myocardial Infarction Contrast Imaging) trial studied myocardial contrast echocardi-
ography within one day of primary PCI. Myocardial contrast echocardiography was
superior to other measurements of no-reflow in predicting which patients would
develop ventricular dilation. A commentary by Grayburn and Choi notes that while
these 2 techniques can accurately assess myocardial perfusion, there is little known
about how to treat or prevent the no-reflow problem. See pages 552, 560,
and 566.
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Heart Failure
Persistent Anemia Is a Significant Risk Factor for Patients With CHF
Although anemia is known to portend a poor outcome in patients with chronicheart failure (CHF), most of these data consist of a single assessment of hemoglo-
bin (Hb) levels. Tang and colleagues used the electronic medical record of their
institution to identify several aspects of anemia in patients with CHF. The prevalence
of anemia (Hb12g/dl formen,11g/dl forwomen)was 17%,but only 3%of these
patients had a documented work-up for the etiology. At 6-month follow-up, 20% of
patients without prior anemia developed new-onset anemia, whereas 43% patients
with anemia had since normalized. Patients with persistent anemia were at increased
risk of death, but not those whose anemia resolved. The authors conclude that anemia
is under-recognized and under-evaluated, and that chronic anemia portends poor
outcomes. See page 569. See figure.
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Valvular Heart Disease
Native Valve Characteristics Can Damage Percutaneously Placed Valves
Percutaneous procedures may reduce the morbidity of aortic valve replacement(AVR), but which stenotic valves are suitable for placement of endovascular
stented valves is not clear. Zegdi and colleagues studied 35 patients undergoing surgical
AVR; after the aorta was opened and cardioplegia obtained, a stented valve was
implanted, visually assessed, and then removed. The subjects then underwent standard
AVR. In patients with stenotic but tricuspid aortic valves, the shape of stent deploy-
ment was triangular or elliptical in 32% of subjects. For subjects with bicuspid valves,
79% of the removed valves were elliptical. These altered shapes resulted in areas for
perivalvular leaks and would likely lead to reduced valve performance over time. This
study suggests that characteristics of the native valve need to be considered when
deploying endovascular valve stents inside of them. See page 579. See figure.
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Heart Rhythm Disorders
Altered Atrial Energy Metabolism Predicts Post-Operative AF
Sustaining atrial fibrillation (AF) seems to require high energy utilization for cellularmetabolism. Mayr and colleagues studied this by collecting atrial tissue samples
from patients undergoing cardiac surgery and then performing a combinedmetabolo-
mic and proteomic analysis. Patients in persistent AF had increased beta-
hydroxybutyrate and increased production of key enzymes necessary for ketolytic
energy production, suggesting that these atria aremetabolizing amino acids to augment
the production of adenosine triphosphate. A low glucose to acetate ratio was found in
patients who developed post-operative AF. Atrial fibrillation is associated with changes
in atrial energy metabolism; whether these changes are the inciting factor or reflect a
damaged atria that is more likely to develop AF remains unknown. See page 585.
See figure.
